The Association of British Insurers (ABI) has published new research as part of its campaign calling for the government to cut Insurance Premium Tax (IPT). The research reveals over two thirds of people (67%) have little or no knowledge of IPT and 50% said they were unaware of the impact that IPT had on their insurance costs.

The Association of British Insurers (ABI) has responded to the Government's Road Safety Strategy, published on 7 January 2026, which aims to reduce the number of people killed or seriously injured on roads in Great Britain. Chris Bose, Director of General Insurance Policy at the ABI, stated that strengthening penalties for dangerous and uninsured driving would help deter high risk behaviours, measures the organisation had previously called for in its 10 point motor roadmap. The ABI noted that measures to improve driver training and ensure vehicles meet modern safety standards would help reduce road casualties. The organisation indicated it would continue working with government and stakeholders on road safety improvements, suggesting consideration of how new drivers can build experience across different road types and conditions after passing their test.

In the Spring Budget 2024, on 6 March 2024, the Chancellor of the Exchequer, the Rt Hon Jeremy Hunt MP, announced that the government is working with the Association of British Insurers (ABI) to finalise a framework for monitoring progress on the Mansion House Compact, which aims to increase investment in unlisted equities by 2030. ABI Director General, Hannah Gurga, notes the ‘crucial role’ that the insurance and long-term savings industry has to play in supporting the Chancellor’s focus on encouraging greater investment in the UK, economic growth and putting savers at the heart of decisions. Gurga highlights the ABI’s Investment Delivery Forum is the ‘driving force behind ensuring the £100bn unleashed from Solvency UK can be invested in green and good projects.’

The Association of British Insurers (ABI)  has released new data showing that in 2023, annuity providers invested £178 billion (65% of their assets) in the UK, primarily in housing, renewable energy and infrastructure projects. The ABI highlights that this investment has supported multiple sectors and generated employment and represents a significant contribution, especially when compared to the estimated 55% of total assets invested by defined benefit (DB) pension schemes in the UK economy. The ABI report titled ‘Powering UK Growth Through Pensions’, outlines the investment strategies of providers in defined contribution (DC) pensions, bulk annuities (which cover employers’ defined benefit (DB) pensions), and individual annuities. The report also discusses the measures required to boost investment in the UK. The report's findings emphasise the significant role that both DC providers and annuity insurers play as investors in the UK economy.

Law360: The Association of British Insurers (ABI) has publicly backed the government's decade-long industrial strategy designed to promote business investment and growth in the UK.

Law360: The government must publish a ‘roadmap’ for the introduction of private sector pensions dashboards, the Association of British Insurers (ABI) said on 2 June 2025, warning that officials will fail to hit targets for public engagement without making the service widely accessible.

The Association of British Insurers (ABI) has reported that four out of five people (81%) are not aware of ‘ad spoofing’, a common tactic used by fraudsters to deceive individuals involved in road traffic accidents into using an unscrupulous website, while believing they are interacting with their insurer. This follows research commissioned by the ABI to assess customer awareness and understanding of insurance fraud. The results also revealed that 69% were unaware of investment fraud, 78% had not heard of data farming, 81% were unaware of account takeovers and 90% had not heard of ghost broking.

Law360: The UK trade body for insurers said on 18 April 2024 that turning the Pension Protection Fund (PPF) into a state-backed consolidator for smaller retirement plans would be a major and unjustified intervention.

Life Sciences analysis: Jamie Hatzel, associate at Bristows, discusses the revisions brought by the Association of the British Pharmaceutical Industry’s (ABPI) 2024 Code of Practice, which will come into force on 1 January 2025, namely the new constitution and complaints procedure for the Prescription Medicines Code of Practice Authority (PMCPA), the revised rules regarding the inclusion of prescribing information in advertisements, and the upgrading of certain practices from ‘optional best practice’ to ‘mandatory’.

The Association of British Pharmaceutical Industry (ABPI) reports that branded medicine sales in the UK reached £14.6bn in 2023/24, with industry payments under the Voluntary Scheme for Pricing, Access and Growth (VPAG) projected to hit £3.5bn in 2025—£1bn above initial forecasts. The analysis shows pharmaceutical companies provided £631m in rebates through NHS England commissioning and Cancer Drug Fund agreements, while VPAS and VPAG schemes together generated £3bn in rebates during 2023/24.

The Association of the British Pharmaceutical Industry (ABPI) has announced on 4 April 2025 that the planned autumn review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to June 2025. The accelerated review aims to address concerns about higher-than-expected payment rates for newer medicines and will align with the government's upcoming 10-year NHS plan and Life Sciences Sector Plan. The review intends to restore predictability and sustainability to the scheme's payment structure.

The Association of the British Pharmaceutical Industry (ABPI) has announced that the government has set the 2026 payment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) at 14.5%, down from 22.9% in 2025. This decline reflects slower growth in NHS use of newer medicines during 2025, meaning the rate calculated under the existing VPAG formula fell below the 15% ceiling agreed in the recent UK–US trade deal. Payment rates for older branded medicines will remain between 10% and 35%, and companies will continue to pay a further 1% voluntary contribution to support investment in UK life sciences infrastructure, bringing the total 2026 rebate for newer medicines to 15.5%.